P8A:SGX
Cordlife Group Ltd
SGD 0.12
0.00%
(0.00) Siku 1
12 Okt, 09:49:20 GMT +8 · SGD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya P8A...
Mtaji wa soko
32.37M
Wastani wa kiasi cha mauzo
elfu 1.22
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
SGD 0.26
Chini kwa wiki 52
SGD 0.10
EPS
-SGD 0.04
Hisa za wawekezaji
267.53M
Idadi ya wafanyakazi
111
Mtaji wa soko
32.37M
Wastani wa kiasi cha mauzo
elfu 1.22
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
SGD 0.26
Chini kwa wiki 52
SGD 0.10
EPS
-SGD 0.04
Hisa za wawekezaji
267.53M
Idadi ya wafanyakazi
111
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
GlobeNewswire
·
dakika 44 zilizopita
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight
Business Wire
·
saa 1 iliyopita
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: FFR to Hold Listing Ceremony and First Investor Day at the Nasdaq Tower on Oct. 26; Three New Robotics Product Offerings Launched
marketscreener.com
·
dakika 9 zilizopita
CECO Environmental Corp. Primary Exchange Listing will Change to Texas Stock Exchange from Nasdaq Global Select
Bloomberg.com
·
saa 2 zilizopita
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
Wasifu
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Kuhusu Cordlife Group Ltd
Afisa Mkuu Mtendaji (CEO)Yiu Pang Fai
Wafanyakazi111
Lilianzishwa2 Mei 2001
Makao makuu-
SektaHealth care provider
Tovuticordlife.com